Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

IDEAYA Biosciences stock price, quote, forecast and news

IDYA
US45166A1025
A2PJPB

Price

42.46
Today +/-
+0
Today %
+0 %
P

IDEAYA Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into IDEAYA Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IDEAYA Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IDEAYA Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of IDEAYA Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into IDEAYA Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing IDEAYA Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IDEAYA Biosciences’s growth potential.

IDEAYA Biosciences Revenue, EBIT and net profit per share

DateIDEAYA Biosciences RevenueIDEAYA Biosciences EBITIDEAYA Biosciences Net Income
2030e953.24 M undefined499.54 M undefined524.38 M undefined
2029e1.18 B undefined414.39 M undefined617.78 M undefined
2028e715.9 M undefined364.77 M undefined255.83 M undefined
2027e299.88 M undefined15.97 M undefined-39.21 M undefined
2026e91.26 M undefined-217.47 M undefined-184.22 M undefined
2025e20.03 M undefined-231.87 M undefined-216.89 M undefined
2024e14.86 M undefined-203.6 M undefined-184.61 M undefined
202323.39 M undefined-134.43 M undefined-112.96 M undefined
202250.93 M undefined-62.5 M undefined-58.66 M undefined
202127.94 M undefined-50.27 M undefined-49.76 M undefined
202019.54 M undefined-35.34 M undefined-34.5 M undefined
20190 undefined-44.27 M undefined-41.98 M undefined
20180 undefined-36.42 M undefined-34.35 M undefined
20170 undefined-14.44 M undefined-11.86 M undefined

IDEAYA Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0000.020.030.050.020.010.020.090.30.721.180.95
----42.1185.19-54.00-39.1342.86355.00228.57139.1364.76-19.10
--------------
00000000000000
-14-36-44-35-50-62-134-203-231-21715364414499
----184.21-185.19-124.00-582.61-1,450.00-1,155.00-238.465.0250.9135.1452.36
-11-34-41-34-49-58-112-184-216-184-39255617524
-209.0920.59-17.0744.1218.3793.1064.2917.39-14.81-78.80-753.85141.96-15.07
19.4819.4812.524.7235.2541.4457.520000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The IDEAYA Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the IDEAYA Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of IDEAYA Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand IDEAYA Biosciences's financial health and stability.

Assets

IDEAYA Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that IDEAYA Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of IDEAYA Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into IDEAYA Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-11-34-41-34-49-58-112
0011122
0000000
11084-17-41-11
-2537182225
0000000
0000000
-12-27-3955-55-87-115
-1-1-10-2-3-2
-8-632-146-69-33-158
-7-613-145-67-29-156
0000000
0000000
171055010814597362
171055012814597362
00019000
0000000
-314133720-2389
-13.98-29.33-40.6654.97-58.42-90.62-117.59
0000000

IDEAYA Biosciences stock margins

The IDEAYA Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IDEAYA Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IDEAYA Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the IDEAYA Biosciences's sales revenue. A higher gross margin percentage indicates that the IDEAYA Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the IDEAYA Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the IDEAYA Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IDEAYA Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IDEAYA Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IDEAYA Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

IDEAYA Biosciences Margin History

IDEAYA Biosciences Gross marginIDEAYA Biosciences Profit marginIDEAYA Biosciences EBIT marginIDEAYA Biosciences Profit margin
2030e0 %52.4 %55.01 %
2029e0 %35.18 %52.44 %
2028e0 %50.95 %35.74 %
2027e0 %5.33 %-13.08 %
2026e0 %-238.31 %-201.86 %
2025e0 %-1,157.9 %-1,083.09 %
2024e0 %-1,369.84 %-1,242.06 %
20230 %-574.85 %-483.05 %
20220 %-122.72 %-115.18 %
20210 %-179.92 %-178.1 %
20200 %-180.86 %-176.56 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

IDEAYA Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The IDEAYA Biosciences earnings per share therefore indicates how much revenue IDEAYA Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IDEAYA Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IDEAYA Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IDEAYA Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IDEAYA Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IDEAYA Biosciences Revenue, EBIT and net profit per share

DateIDEAYA Biosciences Sales per ShareIDEAYA Biosciences EBIT per shareIDEAYA Biosciences Earnings per Share
2030e11.47 undefined0 undefined6.31 undefined
2029e14.17 undefined0 undefined7.43 undefined
2028e8.61 undefined0 undefined3.08 undefined
2027e3.61 undefined0 undefined-0.47 undefined
2026e1.1 undefined0 undefined-2.22 undefined
2025e0.24 undefined0 undefined-2.61 undefined
2024e0.18 undefined0 undefined-2.22 undefined
20230.41 undefined-2.34 undefined-1.96 undefined
20221.23 undefined-1.51 undefined-1.42 undefined
20210.79 undefined-1.43 undefined-1.41 undefined
20200.79 undefined-1.43 undefined-1.4 undefined
20190 undefined-3.54 undefined-3.36 undefined
20180 undefined-1.87 undefined-1.76 undefined
20170 undefined-0.74 undefined-0.61 undefined

IDEAYA Biosciences business model

IDEAYA Biosciences Inc is a biotechnology company focused on the development of cancer therapies. The company was founded in 2015 by Yujiro S. Hata and is headquartered in South San Francisco, California. IDEAYA's business model consists of the discovery and development of precision medicine products based on targeted therapies. Targeted therapies are cancer treatments that aim at the specific characteristics of the tumor and have less harmful effects on normal tissue than traditional chemotherapeutics. IDEAYA specializes in the research and development of cancer drugs in three different areas: precision medicine, synthetic lethality, and resistance mechanisms. The company collaborates closely with leading experts in cancer research to develop innovative therapies. In the field of precision medicine, IDEAYA focuses on the development of products based on genetic alterations that cause specific tumors. These genetic alterations are unique to each type of cancer and each individual, meaning that precision medicine products must be individually tailored to each type of cancer. In the area of synthetic lethality, IDEAYA examines the interactions between cancer cells and their environment. These interactions can involve genetic or proteomic changes that make cancer cells dependent on certain signaling pathways and metabolic processes. IDEAYA develops drugs that exploit these dependencies to block the growth of cancer cells. In the area of resistance mechanisms, IDEAYA investigates the mechanisms that cancer cells develop to become resistant to cancer drugs. This involves the discovery of compounds that can bypass these mechanisms and make the cancer cells sensitive to treatments again. IDEAYA has several products in the pipeline, including Inhibat (IDE196) and polyclonal antibodies. Inhibat (IDE196) is a potent and highly selective BRAF inhibitor used in clinical trials for cancer. Polyclonal antibodies are monoclonal antibodies used in cancer immunotherapy. IDEAYA is a company focused on the development of innovative cancer drugs. The company has a solid foundation in cancer research and works closely with leading experts to develop innovative therapies. The company has several products in the pipeline and is working hard to make a significant contribution in cancer research. IDEAYA Biosciences is one of the most popular companies on Eulerpool.com.

IDEAYA Biosciences SWOT Analysis

Strengths

IDEAYA Biosciences Inc possesses several strengths that contribute to its competitive advantage and potential success in the biotechnology industry. These strengths include:

  • A strong portfolio of innovative drug discovery programs and platform technologies.
  • Experienced and knowledgeable management team with a track record of success in the industry.
  • Strategic collaborations with reputable pharmaceutical companies, providing access to resources and expertise.
  • Well-funded operations, with sufficient capital for research and development activities.
  • A focus on precision medicine and targeted therapies, aligning with current healthcare trends and market demands.

Weaknesses

Despite its strengths, IDEAYA Biosciences Inc also faces certain weaknesses that could pose challenges to its growth and competitiveness:

  • Reliance on a limited number of drug candidates in its pipeline, which increases the risk of failure and lack of diversification.
  • A relatively small and less established market presence compared to larger pharmaceutical companies, making it harder to attract attention and secure partnerships.
  • Potential regulatory hurdles and delays in drug development and approval processes, which could impact time-to-market and profitability.
  • Higher research and development costs associated with early-stage discoveries and clinical trials, resulting in increased financial risks.
  • Competition from well-established biotechnology companies and emerging startups in the field.

Opportunities

IDEAYA Biosciences Inc has several opportunities to maximize its growth potential and expand its market presence:

  • Increasing global demand for personalized medicine and targeted therapies, creating a favorable market environment.
  • Potential partnerships with pharmaceutical giants to leverage their resources, distribution networks, and market reach.
  • Advancements in technology and genomics, providing new avenues for drug discovery and precision medicine.
  • Expanding into international markets, especially emerging economies with a growing demand for innovative healthcare solutions.
  • The possibility of successful clinical trials and FDA approvals, leading to commercialization and revenue generation.

Threats

IDEAYA Biosciences Inc should be mindful of potential threats that could impact its performance and disrupt its strategic objectives:

  • Intense competition within the biotechnology industry, with other companies vying for market dominance and investment opportunities.
  • Potential legal and regulatory challenges, including patent disputes and stricter regulatory requirements.
  • Market volatility and economic downturns, which could limit funding availability and investor confidence.
  • Rapid technological advancements that may render IDEAYA Biosciences Inc's existing platform technologies obsolete.
  • Uncertainties related to reimbursement policies and pricing pressures in the healthcare industry.

IDEAYA Biosciences historical P/E ratio, EBIT, and P/S ratio.

IDEAYA Biosciences shares outstanding

The number of shares was IDEAYA Biosciences in 2023 — This indicates how many shares 57.52 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IDEAYA Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IDEAYA Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IDEAYA Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IDEAYA Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for IDEAYA Biosciences.

IDEAYA Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.52 -0.53  (-0.97 %)2024 Q1
12/31/2023-0.48 -0.52  (-9.04 %)2023 Q4
9/30/2023-0.5 -0.46  (8.82 %)2023 Q3
6/30/2023-0.57 -0.5  (11.93 %)2023 Q2
3/31/2023-0.56 -0.49  (12.52 %)2023 Q1
12/31/2022-0.57 -0.5  (12.74 %)2022 Q4
9/30/2022-0.63 0.04  (106.37 %)2022 Q3
6/30/2022-0.53 -0.57  (-8.39 %)2022 Q2
3/31/2022-0.42 -0.36  (14 %)2022 Q1
12/31/2021-0.32 -0.47  (-48.12 %)2021 Q4
1
2

Eulerpool ESG Scorecard© for the IDEAYA Biosciences stock

Eulerpool World ESG Rating (EESG©)

39/ 100

🌱 Environment

43

👫 Social

35

🏛️ Governance

39

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees42
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

IDEAYA Biosciences list of shareholders

%
Name
Stocks
Change
Date
9.82 % Fidelity Management & Research Company LLC8,160,2067,271,9971/31/2024
5.72 % BlackRock Institutional Trust Company, N.A.4,755,318752,47012/31/2023
4.67 % Federated Hermes Global Investment Management Corp.3,883,600500,00012/31/2023
4.27 % Janus Henderson Investors3,551,8911,828,73112/31/2023
4.24 % T. Rowe Price Associates, Inc.3,521,999523,47212/31/2023
4.17 % The Vanguard Group, Inc.3,465,297504,27512/31/2023
3.60 % State Street Global Advisors (US)2,991,899844,39912/31/2023
3.52 % Adage Capital Management, L.P.2,925,094638,13312/31/2023
3.16 % Deerfield Management Company, L.P.2,630,292361,66412/31/2023
2.65 % Boxer Capital, L.L.C.2,202,812012/31/2023
1
2
3
4
5
...
10

IDEAYA Biosciences Executives and Management Board

Mr. Yujiro Hata48
IDEAYA Biosciences President, Chief Executive Officer, Director (since 2015)
Compensation 3.33 M
Dr. Darrin Beaupre56
IDEAYA Biosciences Chief Medical Officer
Compensation 2.53 M
Mr. Paul Stone59
IDEAYA Biosciences Chief Financial Officer
Compensation 1.8 M
Dr. Michael White58
IDEAYA Biosciences Chief Scientific Officer
Compensation 1.49 M
Mr. Jason Throne52
IDEAYA Biosciences Company Secretary, Chief Legal Officer
Compensation 1.16 M
1
2
3

IDEAYA Biosciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Cyteir Therapeutics Stock
Cyteir Therapeutics
SupplierCustomer0,860,920,910,93--
WuXi AppTec Co H Stock
WuXi AppTec Co H
SupplierCustomer0,200,69-0,350,780,800,81
Roche Holding Stock
Roche Holding
SupplierCustomer0,060,70-0,490,19-0,150,23
Novartis Stock
Novartis
SupplierCustomer-0,080,14-0,67-0,64-0,32-0,13
Pfizer Stock
Pfizer
SupplierCustomer-0,540,59-0,230,50-0,350,22
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer-0,56-0,56-0,67-0,51-0,70-0,39
1

Most common questions regarding IDEAYA Biosciences

What values and corporate philosophy does IDEAYA Biosciences represent?

IDEAYA Biosciences Inc represents a commitment to scientific innovation and improving patient outcomes. The company focuses on developing targeted oncology therapies by leveraging its expertise in synthetic lethality and immuno-oncology. IDEAYA embraces a corporate philosophy centered around collaboration, integrity, and patient-centricity. By actively partnering with leading biopharmaceutical companies and institutions, IDEAYA aims to accelerate the development of transformative medicines. The company's dedication to precision medicine and cutting-edge technologies drives its mission to address unmet needs in oncology and provide hope for patients worldwide. IDEAYA Biosciences Inc is dedicated to delivering value to patients, healthcare providers, and stakeholders through its innovative research and therapeutic advancements.

In which countries and regions is IDEAYA Biosciences primarily present?

IDEAYA Biosciences Inc is primarily present in the United States.

What significant milestones has the company IDEAYA Biosciences achieved?

IDEAYA Biosciences Inc has achieved several significant milestones. The company successfully completed its initial public offering in May 2019. IDEAYA Biosciences Inc also entered into a strategic collaboration with GlaxoSmithKline (GSK) in October 2019 to develop targeted therapies for solid tumors. They have advanced their oncology pipeline, with notable progress in their Synthetic Lethality programs, including the initiation of Phase 1/2 clinical trials. In addition, IDEAYA Biosciences Inc expanded its oncology collaboration with Novartis in December 2019. They have made substantial strides in their research and development efforts, bringing innovative and precision medicine approaches to cancer treatment.

What is the history and background of the company IDEAYA Biosciences?

IDEAYA Biosciences Inc is a clinical-stage oncology-focused precision medicine company. Founded in 2015, IDEAYA is dedicated to leveraging its Synthetic Lethality platform to develop personalized therapies for patients with genetically defined cancers. The company's innovative approach involves using biomarkers to identify patients who are most likely to respond to their targeted cancer therapies. IDEAYA's collaborative partnerships, such as the one with Pfizer, enable it to accelerate the development of its portfolio of drug candidates. With a strong track record and a commitment to improving patient outcomes, IDEAYA Biosciences Inc is well-positioned to make a positive impact in the field of precision oncology.

Who are the main competitors of IDEAYA Biosciences in the market?

The main competitors of IDEAYA Biosciences Inc in the market include leading biopharmaceutical companies such as Bristol-Myers Squibb, Novartis AG, Pfizer Inc, and Roche Holding AG. These companies also operate in the biotechnology sector and offer innovative solutions for various diseases and medical conditions. IDEAYA Biosciences Inc competes with these industry giants through its cutting-edge research and development, strategic partnerships, and focus on targeted therapies for oncology and immuno-oncology. By offering unique approaches to precision medicine, IDEAYA Biosciences Inc aims to carve a niche for itself in the competitive biopharmaceutical market.

In which industries is IDEAYA Biosciences primarily active?

IDEAYA Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of IDEAYA Biosciences?

IDEAYA Biosciences Inc is a precision medicine-focused biotechnology company. Their business model revolves around leveraging their expertise in synthetic lethality and cancer biology to discover and develop targeted oncology therapeutics. By combining their innovative drug discovery platforms and partnerships, IDEAYA aims to address specific genetic alterations in cancer cells. This approach allows them to develop personalized medicines for patients based on the underlying drivers of their disease. IDEAYA's business model is centered on advancing their pipeline of novel therapies and collaborating with strategic partners to bring innovative treatments to patients in need.

What is the P/E ratio of IDEAYA Biosciences 2024?

The IDEAYA Biosciences P/E ratio is -13.23.

What is the P/S ratio of IDEAYA Biosciences 2024?

The IDEAYA Biosciences P/S ratio is 164.32.

What is the AlleAktien quality score of IDEAYA Biosciences?

The AlleAktien quality score for IDEAYA Biosciences is 3/10.

What is the revenue of IDEAYA Biosciences 2024?

The expected IDEAYA Biosciences revenue is 14.86 M USD.

How high is the profit of IDEAYA Biosciences 2024?

The expected IDEAYA Biosciences profit is -184.61 M USD.

What is the business model of IDEAYA Biosciences

IDEAYA Biosciences Inc is a leading biopharmaceutical company focused on the treatment of cancer. The company offers a wide range of products and services aimed at treating cancer at the cellular level. The company has an innovative business model based on the combination of three core elements: research and development, clinical trials, and partnerships. Research and Development IDEAYA Biosciences Inc focuses on developing drugs that have the potential to combat cancer at the cellular level. The company uses a range of technologies and methods to identify and validate potential drug candidates, including its proprietary platforms for drug discovery and development. These platforms enable the company to quickly and efficiently identify and develop promising new therapies. Clinical Trials IDEAYA Biosciences Inc conducts clinical trials to demonstrate the efficacy and safety of new drugs. The company is currently conducting clinical trials at multiple locations worldwide to advance its pipeline of innovative cancer therapies. The clinical trials focus on various types of cancer, such as prostate cancer, breast cancer, advanced melanoma, and others. Partnerships IDEAYA Biosciences Inc collaborates with various leading companies and universities to advance its research. The partnerships include strategic alliances, acquisitions, and collaboration in drug development and manufacturing. Through these partnerships, IDEAYA Biosciences Inc can leverage its resources and bring its products to market faster. Products IDEAYA Biosciences Inc has launched a wide range of products and services focused on cancer treatment. One product highlight, for example, is the proprietary/oncology inhibitor IDEA-316. This drug has shown promising results in preclinical development and has the potential to provide innovative solutions for cancer patients suffering from inhibitor resistance. Overall, IDEAYA Biosciences Inc has an innovative business model aimed at combating cancer at the cellular level. The combination of research and development, clinical trials, and partnerships enables the company to quickly and efficiently identify and develop promising new therapies to help cancer patients.

What is the IDEAYA Biosciences dividend?

IDEAYA Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does IDEAYA Biosciences pay dividends?

The dividend cannot currently be calculated for IDEAYA Biosciences or the company does not pay out a dividend.

What is the IDEAYA Biosciences ISIN?

The ISIN of IDEAYA Biosciences is US45166A1025.

What is the IDEAYA Biosciences WKN?

The WKN of IDEAYA Biosciences is A2PJPB.

What is the IDEAYA Biosciences ticker?

The ticker of IDEAYA Biosciences is IDYA.

How much dividend does IDEAYA Biosciences pay?

Over the past 12 months, IDEAYA Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IDEAYA Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of IDEAYA Biosciences?

The current dividend yield of IDEAYA Biosciences is .

When does IDEAYA Biosciences pay dividends?

IDEAYA Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IDEAYA Biosciences?

IDEAYA Biosciences paid dividends every year for the past 0 years.

What is the dividend of IDEAYA Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IDEAYA Biosciences located?

IDEAYA Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von IDEAYA Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IDEAYA Biosciences from 8/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2024.

When did IDEAYA Biosciences pay the last dividend?

The last dividend was paid out on 8/2/2024.

What was the dividend of IDEAYA Biosciences in the year 2023?

In the year 2023, IDEAYA Biosciences distributed 0 USD as dividends.

In which currency does IDEAYA Biosciences pay out the dividend?

The dividends of IDEAYA Biosciences are distributed in USD.

All fundamentals about IDEAYA Biosciences

Our stock analysis for IDEAYA Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IDEAYA Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.